Biovest International, Inc. (OTCQB:BVTI) today announced that construction has been completed for its new personalized cancer vaccine manufacturing site in Minnesota. The new BiovaxID®-dedicated production suites are part of an expansion project within Biovest’s 35,000 sq. ft. cell culture center in Coon Rapids, a suburb of Minneapolis, with funding provided by a public/private partnership with the State of Minnesota, the City of Coon Rapids and JMS Holdings, LLC. This new production space will accommodate manufacturing for Biovest’s late-stage, autologous, active immunotherapy for the treatment of non-Hodgkin’s lymphoma. BiovaxID was developed in collaboration with the National Cancer Institute, and Biovest is currently preparing for meetings with U.S. and international regulatory agencies to discuss the next steps in seeking approvals for BiovaxID based on positive Phase III clinical trial results.
